31 results
8-K
EX-1.1
TPST
Tempest Therapeutics Inc
20 Jun 24
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
8:13am
or natural person.
(c) Research Analyst Independence. The Company acknowledges that the Agent’s research analysts and research departments are required
PRE 14A
xridtr86ozfkv
22 Apr 22
Preliminary proxy
4:01pm
8-K
EX-1.1
wnrxvd
23 Jul 21
Other Events
5:20pm
424B3
w6q09y33
11 May 21
Prospectus supplement
5:19pm